Pharmacology

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

The detected reduction in HRs for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.

Infants, young children, and older adults are at the highest risk for pneumococcal infection, and viral illnesses, such as influenza, may predispose sensitive groups to pneumococcal infection.

GLP-1 receptor agonists are increasingly being used to treat obesity in adolescents.

Kay Rhee, MD, discusses the challenges of pediatric obesity treatment, highlighting the role of biological and environmental factors, behavioral interventions, and the potential benefits of GLP-1 medications in weight management for children and teens.

A study presented at the 2024 AAP Conference found that white children and those from higher socioeconomic backgrounds are more likely to receive opioid prescriptions for fractures. Despite effective non-opioid alternatives, disparities persist in opioid prescription patterns.

The study points to areas where response efforts can be enhanced, particularly in the identification of opioid poisonings in infants and young children.

On average, participants treated with levacetylleucine for 12 weeks had better fSARA scores compared to when they received a placebo.

In this analysis, the differences in adverse events resulting from JAKi among adults and children were evaluated.

First-generation antihistamine prescriptions were linked to a 22% higher seizure risk in young children, especially those aged 6 to 24 months, according to recent findings.

Biogen's Phase 2/3 study showed a higher dose of nusinersen improves motor function in SMA infants, with plans for regulatory submission to advance treatment.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

"I suspect that some doctors still have not changed their ways, so if you see your ENT, EM, or pediatric colleagues prescribing them, please ask them to stop." - Jon Matthew Farber, MD.

The decision makes pitolisant the first and only FDA-approved, non-scheduled treatment option for daytime sleepiness in this patient population.

The tool, the Kaiser Permanente neonatal EOS calculator, is designed to guide decision making based on objective data available at birth.

The 2 groups did not differ in how likely they were to fill at least 1 prescription of any antibiotic while enrolled in kindergarten.

As safe and effective gene-editing and gene-replacement therapies become more attainable, developing the delivery systems that ensure these treatments are equitably available will be equally essential.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the June 2024 issue of Contemporary Pediatrics.

As teenagers become sexually active, are they fully educated on contraception and pregnancy?

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April 2024 issue of Contemporary Pediatrics.

The resubmission was announced in a first quarter, 2024 earnings news release from Lilly, which expects "regulatory action in the second half of 2024."

The rare genetic disease causes the body's immune system to not function properly.

A decision from the federal agency is expected in the fourth quarter of 2024.

With the approval comes the immediate availability of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses for patients between 2 to 5 years of age.

Study in JAMA: Antenatal corticosteroids don't impact neurodevelopment in late preterm children aged 6 years and up.